Alkem Laboratories Limited went down in its stock price on February 21, 2025, after a major equity deal worth ₹300 crores took place. Around 6.41 lakh shares were sold at a floor price of ₹4,680 per share, which was slightly lower than the previous day's closing price.
So far this year, Alkem Labs' shares have fallen over 16%, reflecting the challenges the company is facing.
Struggles in the key market segment
Alkem Labs has been finding it tough in the Indian pharmaceutical market, particularly in the anti-infective therapy segment, where it usually performs well. The management has acknowledged this slowdown as a key hurdle, with the broader market trends also adding pressure.
The company's Q3 earnings highlighted positive factors such as better gross margins, lower raw material costs, and projected 13-14% growth in non-US markets. Besides, its GLP-1 submission to the Indian regulator is another potential growth driver, making it an interesting option for those looking to buy shares online.
How Alkem Labs performed in Q3
Looking at the numbers, Alkem Labs posted a 5% increase in net profit year-on-year, bringing it to ₹626 crores compared to ₹595 crores in the same quarter last year. Revenue saw a small rise of 1.5%, touching ₹3,374 crores versus ₹3,324 crores a year ago.
The company also improved its operational efficiency, with EBITDA margins going up by 120 basis points to 22.5% from 21.3% in the previous year.
What's next for investors?
With market uncertainties in play, investors are closely watching Alkem Lab's next moves. Some are considering whether to buy shares online now or wait for further developments. The stock's future will depend on how well the company adapts to challenges and maintains steady growth. On February 21, 2025, at 12:10 PM, the stock was trading at ₹4,624.05, down by 2.03%.
As large transactions like this continue to impact the market, those looking to buy shares online should stay informed before making investment decisions.
For android only